Kathy Ling PhD, Director of Business Development, GenScript ProBio USA Inc.
Kathy Ling is the Director of Business Development at GenScript ProBio USA Inc, the Contract Development Manufacturing Organization division of GenScript Biotech Corporation. Kathy brings deep industry, technical and regulatory knowledge in the development of antibody therapeutics, with specialties in antibody discovery, engineering, assay development, production cell line development, and CMC/GMP production for Investigational New Drug (IND) filing. She also has strong expertise in leading cross-functional teams (technical, production, logistics, and licensing). Kathy earned her medical degree from Nanjing University. She then completed her Ph.D. degree from the University of Illinois at Urbana-Champaign and completed her post-doctoral fellowship training. Before joining ProBio, Dr. Ling previously served as Scientific Account Manager and Scientific Advisor for GenScript USA. Kathy can be reached at kathy.ling@genscriptprobio.com. Feel free to contact her, she is committed to providing advice and guidance to our next generation of drug developers.
Single domain antibody (sdAb) is a modality widely used in different therapies including mono/bi-specific antibodies, CAR-T, and ADCs. Animal immunization is a common approach to generate sdAb candidates. However, limited sequence diversity in immunization-derived candidates is a known issue. Here we introduce our integrated sdAb discovery platform built on both immunized and naïve libraries to achieve maximal diversity, generating leads with differentiated profiles for different therapies.
